VESALIUS-CV will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. VESALIUS-CV on ClinicalTrials.gov CONTACT US About VESALIUS